Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$94.13
+1.2%
$96.58
$79.52
$124.00
$23.80B1.361.09 million shs1.04 million shs
CVS Health Corporation stock logo
CVS
CVS Health
$90.50
+3.6%
$76.86
$58.35
$90.89
$115.98B0.68.56 million shs11.14 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$131.33
-2.0%
$139.59
$96.18
$157.29
$163.01B0.316.82 million shs10.25 million shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$2.05
$0.00
$0.00
$84.95M-0.0640.67 million shs760.56 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.35
+12.0%
$51.70
$22.28
$59.55
$21.57B1.059.71 million shs20.80 million shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$379.49
+2.6%
$304.54
$234.60
$387.21
$344.63B0.649.38 million shs6.44 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-2.35%-10.08%+3.79%-12.76%+0.24%
CVS Health Corporation stock logo
CVS
CVS Health
+0.52%+4.67%+11.92%+11.43%+30.76%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.64%+2.46%-3.41%-12.09%+35.55%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
0.00%0.00%0.00%0.00%+204,999,900.00%
Moderna, Inc. stock logo
MRNA
Moderna
-0.51%+5.66%-3.13%+18.36%+101.75%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
+0.69%-0.38%+20.19%+33.69%-5.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$94.13
+1.2%
$96.58
$79.52
$124.00
$23.80B1.361.09 million shs1.04 million shs
CVS Health Corporation stock logo
CVS
CVS Health
$90.50
+3.6%
$76.86
$58.35
$90.89
$115.98B0.68.56 million shs11.14 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$131.33
-2.0%
$139.59
$96.18
$157.29
$163.01B0.316.82 million shs10.25 million shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$2.05
$0.00
$0.00
$84.95M-0.0640.67 million shs760.56 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.35
+12.0%
$51.70
$22.28
$59.55
$21.57B1.059.71 million shs20.80 million shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$379.49
+2.6%
$304.54
$234.60
$387.21
$344.63B0.649.38 million shs6.44 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-2.35%-10.08%+3.79%-12.76%+0.24%
CVS Health Corporation stock logo
CVS
CVS Health
+0.52%+4.67%+11.92%+11.43%+30.76%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.64%+2.46%-3.41%-12.09%+35.55%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
0.00%0.00%0.00%0.00%+204,999,900.00%
Moderna, Inc. stock logo
MRNA
Moderna
-0.51%+5.66%-3.13%+18.36%+101.75%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
+0.69%-0.38%+20.19%+33.69%-5.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.72
Moderate Buy$131.6040.19% Upside
CVS Health Corporation stock logo
CVS
CVS Health
2.85
Moderate Buy$95.926.16% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.86
Moderate Buy$157.5019.91% Upside
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.00
SellN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-33.73% Downside
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
2.69
Moderate Buy$378.880.27% Upside

Current Analyst Ratings Breakdown

Latest UNH, BNTX, CVS, MRNA, GILD, and LPTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetOverweight$102.00 ➝ $103.00
5/8/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Reiterated RatingBuy$155.00 ➝ $157.00
5/8/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Lower Price TargetSector Perform$123.00 ➝ $122.00
5/7/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetOutperform$93.00 ➝ $107.00
5/7/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetOverweight$93.00 ➝ $101.00
5/7/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetBuy$97.00 ➝ $100.00
5/7/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetBuy$98.00 ➝ $102.00
5/7/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetBuy$80.00 ➝ $100.00
5/7/2026
CVS Health Corporation stock logo
CVS
CVS Health
Boost Price TargetBuy$88.00 ➝ $92.00
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$171.00 ➝ $158.00
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetOverweight$150.00 ➝ $140.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.31$1.32 per share71.35$86.54 per share1.08
CVS Health Corporation stock logo
CVS
CVS Health
$402.07B0.29$15.50 per share5.83$60.58 per share1.49
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B5.54$10.09 per share13.02$18.23 per share7.21
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Moderna, Inc. stock logo
MRNA
Moderna
$2.20B9.71N/AN/A$18.67 per share2.89
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$447.57B0.77$21.87 per share17.28$114.40 per share3.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.24N/AN/AN/A-44.39%-5.30%-4.62%N/A
CVS Health Corporation stock logo
CVS
CVS Health
$1.77B$1.3839.7611.070.910.72%11.88%3.54%N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B$6.7719.3113.651.8028.90%49.46%17.81%N/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.22N/AN/AN/AN/A-247.44%-146.51%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%N/A
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$12.06B$13.2428.5318.391.582.68%14.65%4.77%N/A

Latest UNH, BNTX, CVS, MRNA, GILD, and LPTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.91$2.03+$0.12$1.61$6.91 billion$6.96 billion
5/6/2026Q1 2026
CVS Health Corporation stock logo
CVS
CVS Health
$2.21$2.57+$0.36$2.30$94.99 billion$100.43 billion
5/5/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/21/2026Q1 2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$6.76$7.23+$0.47$6.90$109.84 billion$111.65 billion
2/14/2026Q4 2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/A-$0.3870N/A-$1.47N/A$1.06 billion
2/13/2026Q4 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.79-$2.11+$0.68-$2.11$611.14 million$678.00 million
2/10/2026Q4 2025
CVS Health Corporation stock logo
CVS
CVS Health
$1.00$1.09+$0.09$2.30$103.67 billion$105.69 billion
2/10/2026Q4 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.83$1.86+$0.03$1.74$7.68 billion$7.93 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
CVS Health Corporation stock logo
CVS
CVS Health
$2.662.94%+5.87%192.75%4 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.50%+3.04%48.45%10 Years
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$8.842.34%+12.57%66.77%15 Years

Latest UNH, BNTX, CVS, MRNA, GILD, and LPTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.45%6/15/20266/15/20266/29/2026
3/18/2026
CVS Health Corporation stock logo
CVS
CVS Health
quarterly$0.66503.37%4/23/20264/23/20265/4/2026
2/24/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
quarterly$2.213.1%3/9/20263/9/20263/17/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
7.49
CVS Health Corporation stock logo
CVS
CVS Health
0.78
0.87
0.63
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.98
1.55
1.40
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
1.34
1.34
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.69
0.80
0.79

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
CVS Health Corporation stock logo
CVS
CVS Health
80.66%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
87.86%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
CVS Health Corporation stock logo
CVS
CVS Health
0.85%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4.30%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
CVS Health Corporation stock logo
CVS
CVS Health
300,0001.28 billion1.27 billionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million39.66 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
390,000908.14 million905.67 millionOptionable

Recent News About These Companies

Healthcare Stocks To Follow Now - May 8th
Best Healthcare Stocks To Follow Today - May 7th
UnitedHealth: Watch The Recovery In Action
Promising Medical Stocks To Follow Today - May 6th
Healthcare Stocks To Watch Now - May 6th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$94.13 +1.11 (+1.19%)
Closing price 04:00 PM Eastern
Extended Trading
$94.92 +0.79 (+0.84%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

CVS Health stock logo

CVS Health NYSE:CVS

$90.50 +3.14 (+3.59%)
Closing price 03:59 PM Eastern
Extended Trading
$90.16 -0.33 (-0.37%)
As of 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$131.33 -2.73 (-2.04%)
Closing price 04:00 PM Eastern
Extended Trading
$131.00 -0.33 (-0.25%)
As of 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Moderna stock logo

Moderna NASDAQ:MRNA

$54.35 +5.81 (+11.97%)
Closing price 04:00 PM Eastern
Extended Trading
$55.53 +1.18 (+2.18%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

UnitedHealth Group stock logo

UnitedHealth Group NYSE:UNH

$379.49 +9.75 (+2.64%)
Closing price 03:59 PM Eastern
Extended Trading
$379.20 -0.29 (-0.08%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.